Lyra Therapeutics (LYRA) Stock Price, News & Analysis

Company Overview

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $7.05 to $7.40
• 50-Day Range: $6.58 to $13.38
• 52-Week Range: $3.81 to $37.50
• Volume: 5,025 shs
• Average Volume: 14,333 shs
• Market Capitalization: $11.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.00
• Consensus Rating: Hold

Lyra Therapeutics Stock Analysis - MarketRank™

Lyra Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 533rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Lyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Lyra Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyra Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyra Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyra Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lyra Therapeutics has a P/B Ratio of 7.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.08% of the outstanding shares of Lyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently increased by 10.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyra Therapeutics does not currently pay a dividend.

Dividend Growth

Lyra Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.08% of the outstanding shares of Lyra Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Lyra Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyra Therapeutics has recently increased by 10.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Lyra Therapeutics has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

5 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,039.00 in company stock.

Percentage Held by Insiders

Only 3.25% of the stock of Lyra Therapeutics is held by insiders.

Percentage Held by Institutions

95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYRA Stock Analysis - Frequently Asked Questions

How have LYRA shares performed this year?

Lyra Therapeutics' stock was trading at $10.32 at the beginning of 2025. Since then, LYRA stock has decreased by 30.4% and is now trading at $7.18.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) posted its earnings results on Tuesday, August, 12th. The company reported ($5.51) EPS for the quarter, beating the consensus estimate of ($5.79) by $0.28. The company earned $0.29 million during the quarter, compared to analysts' expectations of $0.18 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 404.56% and a negative net margin of 5,043.64%.

When did Lyra Therapeutics' stock split?

Lyra Therapeutics shares reverse split on the morning of Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

Who are Lyra Therapeutics' major shareholders?

Top institutional investors of Lyra Therapeutics include Perceptive Advisors LLC (15.56%), Bank of America Corp DE (1.74%) and Geode Capital Management LLC (0.69%). Insiders that own company stock include Maria Palasis, Jason Cavalier, Perceptive Advisors Llc, Nbvm Gp, Llc and Harlan Waksal.
View institutional ownership trends.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LYRA
• CIK: 1327273
• Web: www.lyratherapeutics.com
• Phone: 617-393-4600
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lyra Therapeutics: $100.00
• High Price Target: $100.00
• Low Price Target: $100.00
• Potential Upside/Downside: +1,292.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($29.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$93.43 million
• Net Margins: -5,043.64%
• Pretax Margin: -5,041.17%
• Return on Equity: -404.56%
• Return on Assets: -60.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.78
• Quick Ratio: 2.78

Sales & Book Value

• Annual Sales: $1.53 million
• Price / Sales: 7.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.99 per share
• Price / Book: 7.25

Miscellaneous

• Outstanding Shares: 1,640,000
• Free Float: 1,592,000
• Market Cap: $11.78 million
• Optionable: Optionable
• Beta: 0.17